Glucosatrin
Natural health product licensed in Canada
- Licence holder
- Market America Inc.
- NPN or DIN-HM
- 80048208
- Status
- Active licence
- Licence date
- 7 February 2014
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine D: up to 20.01 µg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Zinc Source : Sulfate de zinc | 3.33 mg | 9,990 µg |
| Manganèse Source : Sulfate de manganèse (II) monohydraté | 670 µg | 2,010 µg |
| Cuivre Source : Gluconate de cuivre (II) | 0.01 mg | 30 µg |
| Vitamine C Source : Acide ascorbique | 33.33 mg | 99,990 µg |
| Vitamine D Source : Cholécalciférol | 6.67 µg | 20.01 µg |
| Sulfate de glucosamine*chlorure de potassium Source : Exosquelette de crustacés | 500 mg | Not calculated |
Non-medicinal ingredients
phosphate de dicalcium, Silice, Cellulose - microcrystalline, Croscarmellose de sodium, Stéarate de magnésium, Acide stéarique, Glaze, Pharmaceutical NF
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 3 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Glucosatrin helps to relieve joint pain associated with osteoarthritis and protects against the deterioration of cartilage. Its unique formula helps in the development and maintenance of bones, cartilage, teeth and gums, and in the absorption and use of calcium and phosphorus. Glucosatrin also helps in connective tissue formation and in the building of healthy cartilage.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80048208
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.